These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 26417066)
1. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. He C; Mao D; Hua G; Lv X; Chen X; Angeletti PC; Dong J; Remmenga SW; Rodabaugh KJ; Zhou J; Lambert PF; Yang P; Davis JS; Wang C EMBO Mol Med; 2015 Nov; 7(11):1426-49. PubMed ID: 26417066 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-18a targeting of the STK4/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer. Morgan EL; Patterson MR; Ryder EL; Lee SY; Wasson CW; Harper KL; Li Y; Griffin S; Blair GE; Whitehouse A; Macdonald A PLoS Pathog; 2020 Jun; 16(6):e1008624. PubMed ID: 32555725 [TBL] [Abstract][Full Text] [Related]
3. The Hippo component YAP localizes in the nucleus of human papilloma virus positive oropharyngeal squamous cell carcinoma. Alzahrani F; Clattenburg L; Muruganandan S; Bullock M; MacIsaac K; Wigerius M; Williams BA; Graham ME; Rigby MH; Trites JR; Taylor SM; Sinal CJ; Fawcett JP; Hart RD J Otolaryngol Head Neck Surg; 2017 Feb; 46(1):15. PubMed ID: 28222762 [TBL] [Abstract][Full Text] [Related]
4. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma. Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036 [TBL] [Abstract][Full Text] [Related]
5. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Ahn EY; Kim JS; Kim GJ; Park YN Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797 [TBL] [Abstract][Full Text] [Related]
6. Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway. Ehmer U; Sage J Mol Cancer Res; 2016 Feb; 14(2):127-40. PubMed ID: 26432795 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. You B; Yang YL; Xu Z; Dai Y; Liu S; Mao JH; Tetsu O; Li H; Jablons DM; You L Oncotarget; 2015 Feb; 6(6):4357-68. PubMed ID: 25738359 [TBL] [Abstract][Full Text] [Related]
8. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099 [TBL] [Abstract][Full Text] [Related]
9. Targeting YAP and Hippo signaling pathway in liver cancer. Liu AM; Xu MZ; Chen J; Poon RT; Luk JM Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481 [TBL] [Abstract][Full Text] [Related]
10. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung. Lange AW; Sridharan A; Xu Y; Stripp BR; Perl AK; Whitsett JA J Mol Cell Biol; 2015 Feb; 7(1):35-47. PubMed ID: 25480985 [TBL] [Abstract][Full Text] [Related]
11. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway. Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277 [TBL] [Abstract][Full Text] [Related]
12. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner. Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386 [TBL] [Abstract][Full Text] [Related]
13. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis. Li H; Gumbiner BM Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049 [TBL] [Abstract][Full Text] [Related]
14. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750 [TBL] [Abstract][Full Text] [Related]
15. Two faces of Hippo: activate or suppress the Hippo pathway in cancer. Cao J; Huang W Anticancer Drugs; 2017 Nov; 28(10):1079-1085. PubMed ID: 28926422 [TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Chen M; Wang M; Xu S; Guo X; Jiang J Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204 [TBL] [Abstract][Full Text] [Related]
17. ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling. Liu Y; Su P; Zhao W; Li X; Yang X; Fan J; Yang H; Yan C; Mao L; Ding Y; Zhu J; Niu Z; Zhuang T Cancer Sci; 2021 Jul; 112(7):2714-2727. PubMed ID: 33939216 [TBL] [Abstract][Full Text] [Related]
18. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784 [TBL] [Abstract][Full Text] [Related]
19. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma. Wong KF; Liu AM; Hong W; Xu Z; Luk JM Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911 [TBL] [Abstract][Full Text] [Related]
20. YAP/TAZ for cancer therapy: opportunities and challenges (review). Guo L; Teng L Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]